160107-17-5 Usage
Description
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-5-methylis a synthetic derivative of cytidine that is formed by attaching a benzoyl group and two bis(4-methoxyphenyl)phenylmethyl groups to the 5'-O and 5-methyl positions of cytidine, respectively. It has been developed as a potential therapeutic agent for the treatment of various diseases and conditions, including cancer, viral infections, and neurological disorders. It is believed to have potential antitumor and antiviral activities, as well as the ability to enhance cognitive function and improve memory.
Uses
Used in Pharmaceutical Industry:
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-5-methylis used as a potential therapeutic agent for the treatment of various diseases and conditions, such as cancer, viral infections, and neurological disorders. Its potential antitumor and antiviral activities, as well as the ability to enhance cognitive function and improve memory, make it a promising candidate for further research and clinical studies.
Used in Cancer Treatment:
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-5-methylis used as a potential antitumor agent for the treatment of various types of cancer. Its antitumor activity is believed to be due to its ability to inhibit the growth and proliferation of cancer cells, as well as its potential to modulate various signaling pathways involved in cancer progression.
Used in Antiviral Therapy:
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-5-methylis used as a potential antiviral agent for the treatment of various viral infections. Its antiviral activity is believed to be due to its ability to inhibit viral replication and reduce the severity of viral infections.
Used in Neurological Disorders:
Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-5-methylis used as a potential therapeutic agent for the treatment of neurological disorders. Its ability to enhance cognitive function and improve memory makes it a promising candidate for the treatment of conditions such as Alzheimer's disease, Parkinson's disease, and other cognitive impairments.
However, further research and clinical studies are required to fully understand the pharmacological properties and potential therapeutic applications of Cytidine, N-benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-5-methyl-.
Check Digit Verification of cas no
The CAS Registry Mumber 160107-17-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,1,0 and 7 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 160107-17:
(8*1)+(7*6)+(6*0)+(5*1)+(4*0)+(3*7)+(2*1)+(1*7)=85
85 % 10 = 5
So 160107-17-5 is a valid CAS Registry Number.
160107-17-5Relevant articles and documents
Recognition of RNA by tripler formation: Divergent effects of pyrimidine C-5 methylation
Wang, Shaohui,Xu, Yanzheng,Kool, Eric T.
, p. 1043 - 1050 (2007/10/03)
In DNA triple helices, methylation at C-5 of thymine or cytosine is reported to have similar stabilizing effects for both bases. Here we show, however, that methylation of the same positions in RNA triplexes has distinctly different effects than in DNA. We have previously described the use of circular triplex-forming RNA oligonucleotides to recognize RNA sequences. Here it is shown that addition of C-5 methyl groups to uracils in these compounds very significantly increases not only affinity but also sequence selectivity in binding a purine-rich RNA target, as measured by thermal denaturation with various target RNAs. Surprisingly, however, addition of C-5 methyl groups to cytosines actually decreases affinity in binding RNA, while the same substitution in DNB is thermally stabilizing. Possible sources of this divergent behavior are discussed. A synthesis of 5-methylcytidine ribonucleoside 2'-O-silyl-3'-O-phosphoramidite is also described.
